No insider purchase over the last 90 days. The latest was filed 11 Mar 2026.
Agilon Health, Inc. is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). In the past year (18 October 2025 to 18 October 2026), 28 filings came from 7 insiders.
The flow runs one way only: 4 insiders bought (5 purchases totalling €300k) and nobody sold on the market. The totals do not cover 3 filings with an undisclosed amount. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Among those who bought: 4 senior executives. At €256k, the purchase published on 3 March 2026 by Shaker Benjamin is the largest of the period.
The clock since the last published purchase (11 March 2026) now reads 221 days. Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction.
For context, the typical company on the same exchange (median of 5,816 companies) published 19 filings over the same period, against 28 filings here. The full history, which starts in 2021, counts 21 purchases against 13 sales. For the fiscal year to 31 December 2025, the annual 10-K puts revenue at 5.93 bn USD and net income at -391.3 m USD.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
+2 other insiders
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analysts rate Agilon Health, Inc. Buy (bullish), based on 12 analysts. Average price target: US$115.83.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
FY ended December 2025 · cache
25 of 203 declarations
Agilon Health, Inc. is a US-based healthcare company listed on the NYSE under the ticker AGL, in the United States. The company was founded in 2016 and is headquartered in Westerville, Ohio. Its core strategy is built around transforming primary care for seniors by enabling independent primary-care physicians and physician groups to operate in a value-based care model, rather than a fee-for-service structure. Through its purpose-built platform and partnerships, agilon provides capital, data, payer relationships, operational support, and contract expertise so that physicians can focus on the long-term health of their Medicare-age patients. The company describes its model as the Total Care Model, which aims to preserve physician independence while giving local practices the tools to manage full-risk or capitated arrangements for older adults.
From a business-model perspective, agilon health sits in a specialized and competitive corner of the US healthcare market. It is not a traditional insurer or a pure physician practice management roll-up; instead, it is a value-based enablement platform focused on primary care at scale. Its economic performance depends on winning and retaining physician partners, maintaining favorable relationships with Medicare Advantage payers, and managing medical cost trend with discipline. The company’s footprint is national in ambition, but operationally it expands through selected geographies and local market partnerships rather than blanket coverage across the country. Management continues to frame the opportunity around a large and underpenetrated senior-care market in the United States.
Recent developments indicate that agilon is in a demanding transition phase. In its fiscal 2025 results, the company reported revenue of $5.93 billion, down 2% year over year, total members on the platform of 625,000, and a full-year net loss of $391 million. Medical margin turned negative in 2025, reflecting elevated medical cost trends and the impact of market exits. At the same time, management said it had completed actions to improve operating discipline, reduce exposure to downside risk, and right-size the business for a more resilient 2026. In its February 2026 outlook, agilon guided to 2026 adjusted EBITDA roughly around breakeven at the midpoint, signaling a focus on execution rather than aggressive growth.
For investors, the key read-through is that agilon health remains a transformation story. The company operates in a structurally attractive segment tied to senior care, Medicare Advantage penetration, and the shift toward value-based reimbursement. However, the investment case is highly sensitive to clinical cost trends, payer contract economics, physician-partner retention, and the company’s ability to convert scale into sustainable margins. In short, agilon offers a compelling strategic theme, but one that still requires proof of durable financial stability and consistent execution.
Purchases our model currently ranks for the recommendations list.
All recommendations| Fiscal year end | Revenue | Net income | Diluted EPS | Filing |
|---|---|---|---|---|
| Dec 2025 | 5.93 bn USD | -391.3 m USD | n.d. | 10-K |
| Dec 2024 | 6.06 bn USD | -260.2 m USD | n.d. | 10-K |
| Dec 2023 | 4.32 bn USD | -262.6 m USD | n.d. | 10-K |
| Dec 2022 | 2.39 bn USD | -106.6 m USD | n.d. | 10-K |
| Dec 2021 | 1.52 bn USD | -406.5 m USD | n.d. | 10-K |
Amounts in USD, as filed (forms 10-K, 20-F or 40-F). Source: SEC EDGAR.